Jefferies Provides Color On BMR 4Q10

BioMed Realty Trust BMR reported 4Q10 diluted FFO per share of $0.30, “which is above our estimate and consensus of $0.28,” Jefferies reports. “BioMed's focus on the life science industry is a positive given the secular growth drivers of an aging population and demand for healthcare,” Jefferies writes. “However, we would like to see improved leasing in the company's weaker markets to get more constructive on the stock.” BioMed Realty Trust currently trades at $18.20.